Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AB-SA01

Other · Acts on Staphylococcus aureus · developed by Armata Pharmaceuticals

Phase 1 Most advanced trial (none active)

ARMP Developer

2 Registered trials

What is AB-SA01?

AB-SA01 is a bacteriophage therapeutic directed against Staphylococcus aureus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Targets: Staphylococcus aureus
Mechanism: Acts on Staphylococcus aureus
Therapy area: Infectious disease
Developer: Armata Pharmaceuticals, Inc. (ARMP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02757755	Phase 1	Healthy Volunteers	Completed	ARMP
NCT03395769	N/A		No longer available	ARMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Armata Pharmaceuticals

AB-PA01 N/A AP-PA02 Phase 2 AP-SA02 Phase 1/2 C16G2 Phase 2 C16G2 Rinse Phase 2 C16G2 Strip Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARMP page.

Follow ARMP, the company behind AB-SA01

See ARMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARMP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z